GT199900083A - THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY. - Google Patents

THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY.

Info

Publication number
GT199900083A
GT199900083A GT199900083A GT199900083A GT199900083A GT 199900083 A GT199900083 A GT 199900083A GT 199900083 A GT199900083 A GT 199900083A GT 199900083 A GT199900083 A GT 199900083A GT 199900083 A GT199900083 A GT 199900083A
Authority
GT
Guatemala
Prior art keywords
fragility
therapeutic combinations
reduction
procedures
musculoskeletal
Prior art date
Application number
GT199900083A
Other languages
Spanish (es)
Inventor
Hua Zhu Ke
Mei Li
Lidia Codetta Pan
David Duane Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900083A publication Critical patent/GT199900083A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

ESTA INVENCIÒN SE REFIERE A COMPOSICIONES DE COMBINACIÒN FARMACÈUTICA Y PROCEDIMIENTOS, QUE COMPRENDEN A DOS COMPUESTOS INDICADOS COMO FÒRMULA I & II O ALGUNA DE SUS SALES FARMACÈUTICAMENTE ACEPTABLES, SE REFIERE TAMBIEN A PROCEDIMIENTOS DEL USO DE TALES COMBINACIONES Y A ESTUCHES QUE CONTIENEN TALES COMBINACIONES. LAS COMPOSICIONES SON ÙTILES PARA EL TRATAMIENTO DE LA FRAGILIDAD MUSCOLOESQUELÈTICA, INCLUYENDO LA OSTEPOROSIS, FRACTURA OSTEOPORÒTICA , REDUCCIÒN DE MASA ÒSEA, FRAGILIDAD Y REDUCCIÒN DE MASA MUSCULAR.THIS INVENTION REFERS TO PHARMACEUTICAL COMBINATION COMPOSITIONS AND PROCEDURES, WHICH INCLUDE TWO COMPOUNDS INDICATED AS FÒRMULA I & II OR SOME OF ITS PHARMACUTICALLY ACCEPTABLE SALTS, WHICH ARE ALSO USED BY THESE COMMON PROCEDURES AND THE COMPOSITIONS ARE USEFUL FOR THE TREATMENT OF MUSCOLOSKELETAL FRAGILITY, INCLUDING OSTEPOROSIS, OSTEOPORTICAL FRACTURE, REDUCTION OF MASSEA MASS, FRAGILITY AND REDUCTION OF MUSCLE MASS.

GT199900083A 1998-06-16 1999-06-14 THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY. GT199900083A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
GT199900083A true GT199900083A (en) 2000-12-05

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900083A GT199900083A (en) 1998-06-16 1999-06-14 THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY.

Country Status (29)

Country Link
EP (1) EP1085867A1 (en)
JP (1) JP2002518328A (en)
KR (1) KR20010052817A (en)
CN (1) CN1305378A (en)
AP (1) AP9901581A0 (en)
AR (1) AR018868A1 (en)
AU (1) AU3342099A (en)
BG (1) BG105128A (en)
BR (1) BR9911357A (en)
CA (1) CA2335112A1 (en)
CO (1) CO5070586A1 (en)
EA (1) EA200001189A1 (en)
GT (1) GT199900083A (en)
HR (1) HRP20000857A2 (en)
HU (1) HUP0102395A2 (en)
ID (1) ID26726A (en)
IL (1) IL139587A0 (en)
IS (1) IS5727A (en)
MA (1) MA26648A1 (en)
NO (1) NO20006381D0 (en)
OA (1) OA11569A (en)
PA (1) PA8472101A1 (en)
PE (1) PE20000633A1 (en)
PL (1) PL345064A1 (en)
SK (1) SK18902000A3 (en)
TN (1) TNSN99118A1 (en)
UY (1) UY25557A1 (en)
WO (1) WO1999065488A1 (en)
ZA (1) ZA993973B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
BR0113626A (en) * 2000-08-30 2003-06-17 Pfizer Prod Inc Sustained-Release Formulations for Growth Hormone Secretors
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CN100548283C (en) * 2001-11-29 2009-10-14 Gtx公司 Osteoporosis prevention that androgen-deprivation causes and treatment
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (en) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS

Also Published As

Publication number Publication date
TNSN99118A1 (en) 2005-11-10
EA200001189A1 (en) 2001-06-25
MA26648A1 (en) 2004-12-20
HRP20000857A2 (en) 2001-10-31
PL345064A1 (en) 2001-11-19
CA2335112A1 (en) 1999-12-23
AU3342099A (en) 2000-01-05
ID26726A (en) 2001-02-01
PA8472101A1 (en) 2000-09-29
BR9911357A (en) 2001-03-13
OA11569A (en) 2004-07-01
BG105128A (en) 2001-11-30
CN1305378A (en) 2001-07-25
PE20000633A1 (en) 2000-07-26
AR018868A1 (en) 2001-12-12
AP9901581A0 (en) 1999-06-30
WO1999065488A1 (en) 1999-12-23
EP1085867A1 (en) 2001-03-28
JP2002518328A (en) 2002-06-25
SK18902000A3 (en) 2001-12-03
NO20006381L (en) 2000-12-14
ZA993973B (en) 2000-12-15
NO20006381D0 (en) 2000-12-14
UY25557A1 (en) 2001-01-31
HUP0102395A2 (en) 2001-11-28
CO5070586A1 (en) 2001-08-28
IL139587A0 (en) 2002-02-10
IS5727A (en) 2000-11-24
KR20010052817A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
PA8493701A1 (en) COMPOUNDS TO TREAT OBESITY
CR7716A (en) USE OF IKB-KINASE INHIBITORS FOR PAIN TREATMENT
UY28945A1 (en) PIRROLOPIRIDINE DERIVATIVES
UY29265A1 (en) COMPOUNDS OF 3H-OXAZOLO AND 3H-TIAZOLO (4,5, -D) PIRIMIDIN-2-ONA 3,5- DISUSTITUTED AND 3,5,7-TRISUSTITUIDOS AND ITS PROFESSIONALS
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
UY27350A1 (en) AZAINDOLS
ECSP045069A (en) USE OF FLIBANSERINE IN THE TREATMENT OF SEXUAL DISORDERS
BRPI0414867A (en) pyrazolopyridines and their analogues
DK1309589T3 (en) Urea Compounds and Methods of Use
ES2064130T3 (en) USE OF DROLOXIFENO FOR THE TREATMENT OF DISEASES OF THE BONES.
UY28931A1 (en) USED PIRROLOTRIAZINE DERIVATIVES TO TREAT HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
UY27939A1 (en) COMPOUNDS
PT1259512E (en) PTERIDIN COMPOUNDS FOR PSORIASIS TREATMENT
ECSP034810A (en) DERETADOS HETEROCICLILALCOXI-, -ALQUILTIO- Y - ALQUILAMINOBENZAZOL SUCH AS LIGANDOS 5-HIDROXITRIPTAMINA-6
BRPI0418099A (en) compounds, pharmaceutical composition, and use of a compound
PA8635901A1 (en) NUCLEOSIDS OF 3-BETA-D-RIBOFURANOSILTIAZOLO [4,5-D] PYRIMIDINE AND USES OF THE SAME
CO5611124A2 (en) BENZOFURAN DERIVATIVES SUBSTITUTED USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
ECSP055958A (en) 4-AMINOPIRIMIDINA-5-ONA
CL2011002766A1 (en) Carboxamide derived compounds, calpain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of neurodegenerative diseases, alzahimer, pain, among others.
BRPI0411673A (en) compound, pharmaceutically acceptable salt, pharmaceutical composition, and use of a compound
GT199900083A (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY.
UY28535A1 (en) DERIVATIVES OF BENCIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION AND USES OF THE SAME.
UY27324A1 (en) NEW NAPSILATE SALTS I
DE602004009166D1 (en) New analogues of nitrobenzylthioinosine